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In Brief
Mice with Kit mutations have several
immune and non-immune abnormalities,
including mast cell deficiency, and are
protected from weight gain and insulin
resistance during diet-induced obesity.
Gutierrez et al. show that this protection is
not mediated by mast cell deficiency, as
previously thought, but instead through
hematopoietic Kit deficiency.
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Obesity, insulin resistance, and related pathologies
are associated with immune-mediated chronic
inflammation. Kit mutant mice are protected from
diet-induced obesity and associated co-morbidities,
and this phenotype has previously been attributed to
their lack of mast cells. We performed a comprehen-
sive metabolic analysis of Kit-dependent KitW/Wv
and Kit-independent Cpa3Cre/+ mast-cell-deficient
mouse strains, employing diet-induced or genetic
(LepOb/Ob background) models of obesity. Our re-
sults show that mast cell deficiency, in the absence
of Kit mutations, plays no role in the regulation of
weight gain or insulin resistance. Moreover, we pro-
vide evidence that the metabolic phenotype
observed in Kit mutant mice, while independent of
mast cells, is immune regulated. Our data under-
score the value of definitive mast cell deficiency
models to conclusively test the involvement of this
enigmatic cell in immune-mediated pathologies and
identify Kit as a key hematopoietic factor in the path-
ogenesis of metabolic syndrome.
INTRODUCTION
The inflammatory basis for obesity-induced insulin resistance
wasput forthupon thediscoveryof elevated levelsof TNF-a in ad-
ipose tissue (AT) of obese humans and diet-induced obese mice
(Hotamisligil et al., 1995; reviewed inMcNelis andOlefsky, 2014).
Subsequently, numerous studies revealed a complex cascade of
events at the intersection of both inflammatory and insulin
signaling pathways. Macrophages, neutrophils, eosinophils,
CD4+ T cells, CD8+ T cells, T regulatory cells (Treg), B cells, innate
lymphoid cells (ILC) 2, and NKT cells have all been shown to be
involved in the regulation of the inflammatory status of AT and
other metabolic organs, and thus in the development of insulin
resistance and type 2 diabetes (T2D) (reviewed in Mathis, 2013).
Recently, a positive correlation between mast cell content and
hallmarks of AT inflammation in obese humans and diet-induced
obese mice has been reported (Altintas et al., 2011; Divoux678 Cell Metabolism 21, 678–691, May 5, 2015 ª2015 Elsevier Inc.et al., 2012; Liu et al., 2009; Tanaka et al., 2011). This correlation
prompted studies of the effects of ‘‘mast cell deficiency’’ on AT
inflammation, insulin resistance, and T2D in diet-induced obese
KitW/Wv and KitW-sh/W-sh mice, which revealed that Kit mutant
mice were protected from weight gain and insulin resistance (Liu
et al., 2009; Tanaka et al., 2011). Because Kit mutant mice are
mast cell deficient, these experiments raised the intriguing possi-
bility that lack of mast cells was underlying disease resistance.
Mast cells are classically known as effector cells for IgE-medi-
ated allergic inflammation. Based on work in Kit mutant mice, a
plethora of phenotypes beyond allergy has also been attributed
to mast cells. These mice have, in addition to their mast cell defi-
ciency, pleiotropic defects including abnormalities in hematolog-
ical parameters (anemia, megakarocytosis, thrombocytosis),
innate (neutropenia or neutrophilia and expanded myeloid
derived suppressor cells [MDSCs]) and adaptive (decreased
numbers of gd T cells and Treg and increased numbers of ab
T cells) immunity, splenomegaly, lack of intestinal pacemaker
cells of Cajal, deficiency of melanocytes, and cardiomegaly
(Kiss et al., 2011; Maeda et al., 1992; Michel et al., 2013; Nigrovic
et al., 2008; Piconese et al., 2011; Puddington et al., 1994; Rus-
sell, 1979; Waskow and Rodewald, 2002; Zhou et al., 2007). To
‘‘bypass’’ these manifold defects, the ‘‘mast cell knockin’’ tech-
nique (Kawakami, 2009; Nakano et al., 1985) was developed.
This technique employs intravenous transplantation of large
numbers of in vitro-generated bone-marrow-derived mast cells
(BMMCs) into Kit mutant mice, and any phenotype reversal
has been attributed to mast cell function. Indeed, upon mast
cell reconstitution, Kit mutant mice became susceptible to the
development of insulin resistance and T2D (Liu et al., 2009; Ta-
naka et al., 2011); hence, this phenotype was attributed to
mast cells and mast-cell-dependent factors.
Kit-independent mast-cell-deficient mice have recently been
generated, and alarmingly, many, if not most, re-visited ‘‘mast-
cell-dependent’’ phenotypes have not been confirmed (Antsi-
ferova et al., 2013; Dudeck et al., 2011; Feyerabend et al.,
2011; Gomez-Pinilla et al., 2014; Gutierrez et al., 2014; Peschke
et al., 2015; Rodewald and Feyerabend, 2012; Scho¨nhuber
et al., 2014; Willenborg et al., 2014). These unexpected results
demonstrated that experiments in the traditional Kit mutant
models, even in combination with mast cell transplantation,
are unreliable. Hence, it is mandatory to revisit previously
claimed mast-cell-dependent phenotypes in Kit-independent
mast-cell-deficient mice. Despite lack of such independent
confirmation, mast cells have been functionally linked to
obesity and insulin resistance in over 30 reviews since the orig-
inal publication by Liu et al. (2009), and consequently mast cell-
stabilization has been proposed as a novel medication for
obesity and diabetes (Wang and Shi, 2011). Given the implica-
tions and therapeutic potential of mast cell inhibition on these
widespread diseases, we now separated effects of Kit
deficiency from mast cell deficiency on obesity and its associ-
ated co-morbidities. Metabolic phenotyping of the Kit-depen-
dent KitW/Wv and Kit-independent Cpa3Cre/+ mast-cell-deficient
mice during diet-induced or genetic (LepOb/Ob background)
obesity revealed that mast cell deficiency alone plays no role
in the regulation of weight gain, insulin resistance, or T2D.
Instead, the metabolic phenotype of Kit mutant mice, while in-
dependent of mast cells, is immune regulated, which identifies
Kit as a key hematopoietic gene in the pathogenesis of meta-
bolic syndrome.
RESULTS
Mast Cell Deficiency Does Not Protect Mice from
Obesity and Insulin Resistance
Cpa3Cre/+ mice are wild-type for Kit (Kit+/+) but are constitutively
mast cell deficient due to the genotoxicity of strong Cre recom-
binase expression from the Cpa3 locus in mast cells. Besides
their mast cell deficiency and a reduction of basophils,Cpa3Cre/+
mice present no other known immunological or non-immunolog-
ical abnormalities (Feyerabend et al., 2011). To separate the po-
tential roles of mast cells from the effects of Kitmutations in this
disease, we placed mast-cell-deficient C57BL/6 (B6.Cpa3Cre/+)
mice or mast-cell-proficient littermate controls (B6.Cpa3+/+) on
a high-fat diet (HFD) (60% kcal from fat; 35% fat content) for
16 weeks. Surprisingly, when compared to mice fed normal
chow (low-fat diet [LFD]; 6% fat content), both B6.Cpa3Cre/+
and B6.Cpa3+/+ mice showed identical weight gain (Figure 1A).
After 16 weeks of HFD feeding, body composition assessed by
ECHO-MRI revealed no effects of mast cell deficiency on total
AT (Figure 1B) or total lean mass (Figure S1A). In support of
this, epididymal (Figure 1C) and perirenal AT mass (Figure S1B)
were comparable in B6.Cpa3Cre/+and B6.Cpa3+/+ mice. Like-
wise, liver and spleen weight were unaffected by mast cell defi-
ciency (Figures S1C and S1D).
Next, we investigated the abundance of mast cells in AT
before and after HFD-induced obesity. In agreement with earlier
reports (Liu et al., 2009; Tanaka et al., 2011), both frequencies
(Figures 1D and 1E) and absolute numbers (not shown) of mast
cells were increased in obese compared to lean B6.Cpa3+/+
AT, whereas obese B6.Cpa3Cre/+mice remained fully mast-cell-
deficient based on flow cytometric analysis for mast cells
(defined as CD45+IgE+CD117+ cells) (Figure 1D) and on expres-
sion of the mast-cell-specific marker genes Cpa3 (data not
shown) andCma1, which encodes Chymase 1 (Figure 1E). Histo-
logical analysis of AT confirmed the increased mast cell density
in obese compared to non-obese B6.Cpa3+/+ mice, while mast
cells were absent in both obese and non-obese B6.Cpa3Cre/+
tissues (Figure 1F). Collectively, mast cells are induced in obese
fat tissue in wild-type mice but remain undetectable in
B6.Cpa3Cre/+ mice regardless of feeding conditions. Given that
weight gain was indistinguishable between B6.Cpa3+/+ andCB6.Cpa3Cre/+ mice, we conclude that lack of mast cells does
not prevent diet-induced obesity.
To probe the potential role of mast cells in a genetic model of
obesity, we generated B6.LepOb/ObCpa3Cre/+mice that, in addi-
tion to their mast cell deficiency, lack leptin. B6.LepOb/Ob
Cpa3Cre/+ mice were compared to their mast-cell-proficient
B6.LepOb/ObCpa3+/+ as well as to their lean B6.LepOb/+Cpa3+/+
and B6.LepOb/+Cpa3Cre/+ littermates (Figures 1G–1J). Of note,
as in the diet-induced model, mast cell frequencies were
elevated in obese compared to lean controls, and this increase
was only observed in B6.LepOb/ObCpa3+/+ and not in
B6.LepOb/ObCpa3Cre/+ mice (Figure 1J). In this model, in support
of the diet-induced obesity studies, mast cell deficiency did not
affect weight gain (Figure 1G), total adiposity (Figure 1H), or
epididymal AT mass (Figure 1I).
After HFD feeding in the B6.Cpa3Cre/+ and B6.Cpa3+/+ mice,
numbers of total CD45+ leukocytes were increased in visceral
AT (Figure 2A). This increase in cell numbers was paralleled by
elevated absolute numbers of macrophages (Figure 2B). Cellular
dissection of the CD45+ compartment showed a slight increase
in the proportions of macrophages and decreases in proportions
of eosinophils and B cells, while proportions of T cells remained
unaffected by HFD feeding (Figures 2C–2F). Within the T cell
compartment, proportions of total CD4+ T cells and Treg
were unchanged, while proportions of CD8+ T cells were
elevated (Figures 2G–2I) after HFD feeding. All of these parame-
ters reflect the expected responses to HFD feeding; however,
none of these populations were affected by mast cell deficiency
(Figures 2A–2I).
Epididymal AT (Figures 2J–2M), liver and muscle (Figures
S2A–S2H) from LFD- or HFD-fed B6.Cpa3Cre/+ and B6.Cpa3+/+
mice were analyzed for mRNA expression of inflammatory
markers. The cytokine TNF-a is one of the main mediators of
AT inflammation and insulin resistance (Uysal et al., 1997), and
mast cells can produce TNF-a (Gordon and Galli, 1990); how-
ever, the HFD-feeding-associated increase in TnfmRNA expres-
sion in AT was mast cell independent (Figure 2J). Similarly, the
upregulated expression by HFD feeding of the macrophage
marker Emr1 (also known as F4/80) (Figure 2K) and the mono-
cyte/macrophage chemoattractant and inflammatory cytokine
Ccl2 (Figure 2L) were unaffected bymast cell deficiency. Expres-
sion of Il6 in AT tissuewas not increased byHFD-feeding but was
significantly higher in LFD-fed B6.Cpa3Cre/+ mice in comparison
to their LFD B6.Cpa3+/+ littermate controls (Figure 2M), the rele-
vance of which remains to be determined. The expression of
these inflammatory markers was also assessed in liver and mus-
cle, and with the exception of Il6 expression in muscle of lean
mice, mast cell deficiency had no effects on these parameters
(Figures S2A–S2H). In contrast to AT tissue, numbers of mast
cells were not increased (muscle) or induced (liver) in response
to HFD, and they remained undetectable in B6.Cpa3Cre/+ mice
(Figures S2I–S2L).
Glucose homeostasis and insulin resistance during diet-
induced obesity were assessed by glucose tolerance tests
(GTTs) (Figure 2N), fasting plasma insulin (Figure 2O), circu-
lating plasma insulin 45 and 120 min post glucose bolus
injection (Figures S1E and S1F), and Serine-473 Akt phos-
phorylation in epididymal AT (Figures S1G and S1H), gastroc-
nemius muscle, and liver (data not shown) 15 min post-insulinell Metabolism 21, 678–691, May 5, 2015 ª2015 Elsevier Inc. 679
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bolus injection. Mast cell deficiency did not affect glucose
homeostasis, insulin resistance, or T2D. Moreover, mast cell
deficiency did not affect glucose tolerance (Figure 2P) or
fasting insulin levels (Figure 2Q) in the leptin-deficient obese
model. Finally, pharmacological inhibition of mast cell degranu-
lation with disodium chromoglycate (DSCG) had no effect on
weight gain in HFD-fed mast cell-proficient, or -deficient mice
(Figure 2R).
Kit Deficiency Protects Mice from Diet-Induced Obesity
and Metabolic Syndrome
To address the impact of Kitmutations on obesity and the meta-
bolic syndrome, we dissociated mast cell deficiency from Kit
deficiency in WB 3 C57BL/6 (WBB6F1) mice, which is the his-
torical background strain of all experiments using KitW/Wv
mice, including the reported metabolic studies (Liu et al.,
2009; Tanaka et al., 2011). We generated WBB6F1.Kit+/+
Cpa3+/+ (Kit wild-type; mast cell-proficient) (termed Cpa3+/+
below), WBB6F1.Kit+/+Cpa3Cre/+ (Kit wild-type; mast cell defi-
cient) (termed Cpa3Cre/+ below), and WBB6F1.KitW/WvCpa3+/+
(severely impaired Kit signaling due to the compound Kit muta-
tions; mast cell deficient) (termed KitW/Wv below). Breedings
were set up to generate sufficient numbers of littermates for
side-by-side comparisons.
At 8 weeks of age, before the start of HFD feeding, mice of
all genotypes had similar body mass (Figure 3A); however,
KitW/Wv mice were hyperglycemic in comparison to both
Cpa3+/+ and Cpa3Cre/+ mice (Figure 3B). In agreement with pre-
vious reports (Liu et al., 2009; Tanaka et al., 2011), when
placed on an HFD, KitW/Wv mice failed to gain weight, while
both mast cell-proficient Cpa3+/+ and mast-cell-deficient
Cpa3Cre/+ littermate controls showed indistinguishable weight
gain curves (Figure 3C; see Figure S3A for comparison to
LFD controls). No differences were found in food intake be-
tween groups (data not shown). Body composition analyses
by ECHO-MRI after 16 weeks of HFD-feeding showed a
>2-fold reduction in percent adiposity, as well as a significant
reduction in total lean mass in the KitW/Wv when compared to
Cpa3+/+ and Cpa3Cre/+ mice (Figures 3D and 3E). Upon tissue
collection, KitW/Wv mice had a 3-fold lower epididymal (Fig-
ure 3F) and perirenal AT mass (Figure S3B) compared toFigure 1. Weight Gain, Glucose Tolerance, and Insulin Resistance Are
Induced Obesity
(A–F) Male 8-week-old B6.Cpa3Cre/+ mice and their B6.Cpa3+/+ littermate contr
16 weeks. (n = 11–21 per group).
(B) Percent adiposity (total fat/total body mass) determined by ECHO-MRI.
(C) Epididymal AT mass.
(D) Mast cell content in epididymal AT assessed by flow cytometry. Percentage
(E) mRNA expression of Cma1 in epididymal AT.
(F) Metachromatic mast cells (red arrows) visualized in paraffin embedded epid
sentative of three independent experiments.
(G–J) The weights of male B6.LepOb/ObCpa3Cre/+ mast-cell-deficient mice and the
controls, all kept on a LFD, were tracked weekly between 6 and 22 weeks of age
(H) Percent adiposity.
(I and J) (I) Epididymal AT mass and (J) mast cell content in epididymal AT of gen
Data are shown as mean ± SEM and are pooled from two or three independent
Each dot in the dot plots represents one individual mouse. One-way ANOVA or tw
calculate statistical differences. *p < 0.05; **p < 0.01; ****p < 0.0001 between obe
####p < 0.0001 between mast-cell-deficient B6.Cpa3Cre/+ and their respective m
CCpa3+/+ and Cpa3Cre/+ mice. AT of Cpa3Cre/+ and KitW/Wv
mice remained fully mast cell deficient (Figure 3G). The propor-
tions of macrophages from total CD45+ cells were not changed
between groups (Figure S3C); however, absolute macrophage
numbers (Figure S3D), percent eosinophils (Figure S3E), and
percent T cells (Figure S3F) were significantly affected in the
KitW/Wv mice. The proportions of CD8+ and CD4+ cells within
the T cell compartment were not changed in either group (Fig-
ures S3G and S3H).
While Cpa3+/+ and Cpa3Cre/+ mice displayed the expected
normal response to HFD feeding, KitW/Wv mice showed alter-
ations in lipid profiles, glucose tolerance, and insulin resistance
during obesity. KitW/Wv mice presented hypertriglyceridemia
and reduced fasting total plasma cholesterol levels (Figures
3H and 3I) after 16 weeks of HFD feeding; however, Cpa3Cre/+
mice were not different from Cpa3+/+ mice; hence, these
changes in lipid profiles are mast cell independent. Assessment
of glucose tolerance (Figure 3J), fasting plasma insulin (Fig-
ure S3I), and plasma insulin 30 min after glucose bolus injection
(Figure S3J) confirmed that KitW/Wv mice are protected from
diet-induced glucose intolerance and insulin resistance (Liu
et al., 2009; Tanaka et al., 2011). However, this protection in
WBB6F1 mice is not mediated by mast cells because Kit-
independent mast-cell-deficient Cpa3Cre/+ mice lacked this
resistance.
Profound Effects of Kit Deficiency on White AT mRNA
Transcriptome
We compared global gene expression patterns in AT from
KitW/Wv mice versus Cpa3Cre/+ or Cpa3+/+ mice under either
LFD or HFD feeding conditions. Total RNA was collected from
epididymal AT of KitW/Wv,Cpa3Cre/+, andCpa3+/+ mice fed either
a LFD or HFD for 12 weeks (Figure S3A), and gene expression
was examined by whole-transcriptome microarray analysis.
After normalization using the quantile method, data were visual-
ized using a principal component analysis. As shown in Fig-
ure 4A, the largest component of variance is represented in the
x axis (PC1), which corresponds to HFD feeding (black oval)
versus LFD feeding (red rectangle).
Of note, KitW/Wv mice, despite HFD feeding (red dots), fell
into the LFD group (red rectangle in Figure 4A), stronglyUnaffected by Mast Cell Deficiency in Models of Diet- and Genetic-
ols were placed on a LFD or HFD and their weights were tracked weekly for
of CD117 (Kit)+IgE+ mast cells from total CD45+ cells.
idymal AT by toluidine blue staining; images are from one experiment repre-
ir B6.LepOb/ObCpa3+/+, B6.LepOb/+Cpa3Cre/+, and B6.LepOb/+Cpa3+/+littermate
(n = 4–8).
etically obese leptin-deficient mice assessed as described above.
experiments.
o-way ANOVA with a Tukey’s post hoc test (weight gain curves) were used to
se (diet induced or genetic) and their corresponding lean controls. ##p < 0.01;
ast-cell-proficient B6.Cpa3+/+ littermate controls.
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suggesting that KitW/Wv mice lack the normal response to HFD
feeding. To analyze the impact of Kit deficiency on global
gene expression under HFD feeding conditions, we compared
Kit+/+ (regardless of whether they have a Cpa3+/+ or Cpa3Cre/+
genotype) to KitW/Wv mice; we found that 2,190 genes were
significantly differentially regulated in AT by the Kit mutation
(heatmap shown in Figure 4B). A graphical fold-change com-
parison displays the 15 most highly differentially expressed
genes between Kit+/+ and KitW/Wv HFD-fed mice (Figure 4C).
Further analysis identified the strongest differences in gene
expression comparing LFD- and HFD-fed Kit wild-type mice
in genes that were typically upregulated (i.e., Tph2, Trem2, It-
gad, and Gpnmb) or downregulated (i.e., Acsm3 and Pck1) in
AT with obesity (Figure 4D). Strikingly, the pattern of differen-
tial gene expression comparing LFD- versus HFD-fed wild-
type mice (Figure 4D) resembled that of HFD-fed Kit+/+ versus
HFD-fed KitW/Wv mice (Figure 4C), providing further evidence
that Kit mutant mice placed on a HFD remain on a metaboli-
cally ‘‘lean’’ gene expression program.
Kit+/+ BoneMarrowTransplantation intoKitMutantMice
Reverses the Immune andMetabolic Phenotype without
Rescue of the Gut Motility Defect
Kit mutant mice suffer from many mast-cell-independent im-
mune abnormalities described above. Additionally, they have
marked defects outside of the immune system, including
lack of cells of Cajal, which impairs gut motility (Huizinga
et al., 1995; Maeda et al., 1992; Reber et al., 2012; Sergeant
et al., 2002), the development of spontaneous stomach ulcers
(Shimada et al., 1980), forestomach papillomas (Kitamura
et al., 1980), abnormal liver function (Magnol et al., 2007),
and insulin secretion from b cells (Feng et al., 2012), which
could all affect the metabolic phenotype of these mice. There-
fore, we addressed by bone marrow transplantation whether
defects in hematopoietic or non-hematopoietic Kit expression
were underlying the resistance of Kit mutant mice to obesity.
WBB6F1.KitW/Wv mice accept syngeneic Kit+/+ hematopoietic
stem cells (HSCs) without irradiation (Waskow et al., 2009
and references therein), resulting in an adult hematopoietic
system of donor (Kit+/+) origin (Figure S4; data not shown).
Engrafted mice showed reversal of all the Kit-mutation-depen-
dent abnormalities tested, including normalized hematocrit
(Figure 5A), increased ILC3 levels, and normalized intraepithe-Figure 2. Mast Cell Deficiency Does Not Affect AT Immune Infiltration
(A–O) Immunological and metabolic parameters of B6 mice with or without mast
(A–F) (A) Absolute numbers of CD45+ leukocytes and (B) CD11b+F4/80+ macr
CD11blowF4/80lowSiglec-F+ eosinophils (D), CD19+CD3ε B cells (E), and CD3ε+
(G–I) Percentages of CD4+ T cells (G) and CD8+ T cells (H) from total CD3ε+ T ce
(J–M) Total RNA was isolated from epididymal AT, and the expression of inflamm
Emr1 (K), Ccl2 (L), and Il6 (M) in epididymal AT.
(N) GTT performed at 14 weeks of diet feeding (n = 11–21).
(O) Fasting plasma insulin after 16 weeks of HFD feeding.
(P and Q) Metabolic analyses of leptin-deficient mice with and without mast cells
(P) GTT performed at 19 weeks of age (n = 4–8).
(Q) Fasting plasma insulin at 22 weeks of age.
(R)Male 8-week-old B6.Cpa3Cre/+ mice and their B6.Cpa3+/+ littermate controls w
and their weights were tracked weekly; an additional control group was not injec
Data are shown as mean ± SEM and are pooled from three independent experime
Statistics were performed as described for Figure 1 above. *p < 0.05; **p < 0.01; ***
(diet or leptin effect). #p < 0.01 between B6.Cpa3Cre/+ and their respective B6.Cp
Clial TCR gd+ and TCR ab+ T cells (data not shown). In
contrast, bone marrow transplantation could not reverse the
gut motility defect associated with lack of cells of Cajal (Fig-
ure 5B), despite contrary reports (Ishii et al., 2009). We also
reconstituted WBB6F1.KitW/Wv mice with WBB6F1.Cpa3Cre/+
bone marrow, which led to completely normalized stem and
progenitor cell compartments (Figure S4B; data not shown),
and that of all other tested Kit mutation-dependent immune
abnormalities except for mast cells (analyzed in peritoneal
cavity and AT; data not shown).
Despite the major non-immunological abnormalities that
cannot be overcome by hematopoietic reconstitution, Kit+/+
HSC transplantation reversed all analyzed metabolic pheno-
types of KitW/Wvmice; that is, it normalized base line hyperglyce-
mia (Figure 5C), weight gain during HFD-feeding (Figure 5D), and
loss of protection from glucose intolerance (Figure 5E). The
rescue was similar in mice reconstituted with wild-type
(Cpa3+/+) or mast-cell-incompetent (Cpa3Cre/+) bone marrow.
Bone marrow transplantation also normalized total AT mass,
epididymal AT mass, and total lean mass after HFD feeding (Fig-
ures 5F–5H).
Kit-Mutation-Dependent Metabolic Defects Are Not
Replicated by Absence or Perturbations in Immune
Lymphoid Lineages
One of the main immune phenotypes associated with Kit muta-
tions is abnormal lymphopoiesis that includes abnormal T cell
development in the thymus (Waskow et al., 2002; Waskow
and Rodewald, 2002), reduced Treg cells (Piconese et al.,
2011), decreased intraepithelial TCR gd+ T cells and increased
numbers of intraepithelial TCR ab+ T cells in the gut (Puddington
et al., 1994), and reduced levels of ILC3s (Chappaz et al., 2010;
Kiss et al., 2011). The potential impact of perturbations in
lymphoid lineages on the metabolic phenotype was examined
in B6.Rag2/mice, which completely lack mature B and
T cells and have increased ILC3 levels, and in B6.Il7r/ mice
that lack the receptor for the key lymphopoietic factor IL-7,
and thus have severe immunodeficiencies in T and B cell and
innate lymphoid lineages. The metabolic phenotype of these
mutants was compared to wild-type mice (B6.Il7r+/ littermate
controls of the B6.Il7r/ mice). In contrast to the Kit muta-
tion-dependent phenotype, B6.Rag2/ and B6.Il7r/ mice
had normal or even increased (former) weight gain inor Inflammatory Status
cells after 16 weeks of LFD or HFD feeding.
ophages per 0.5 g of AT. Percentages of CD11b+F4/80+ macrophages (C),
CD19 T cells from total CD45+ cells (F).
lls. Percentage of Foxp3+ Treg from total CD4+ T cells (I).
atory genes was assessed by quantitative real-time PCR. Expression of Tnf (J),
.
ere placed onHFD for 7 weeks and injected daily with 25mg/kg DSCGor saline,
ted (n = 4–10).
nts (DSCG study: one experiment); each dot represents one individual mouse.
p < 0.001; ****p < 0.0001 between obesemice and their respective lean controls
a3+/+ littermate controls in the same diet (Cpa3Cre/+ genotype effect).
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Figure 3. Kit Deficiency Protects from Diet-Induced Obesity and Insulin Resistance
WBB6F1.KitW/Wv, WBB6F1.Cpa3+/+, and WBB6F1.Cpa3Cre/+ mice were used to dissect the effects of Kit deficiency versus mast cell deficiency during diet-
induced obesity.
(A and B) (A) Total body mass and (B) fasting plasma glucose of 8-week-old male mice were assessed before HFD feeding.
(C) Mice were placed on an HFD for 16 weeks starting at 8-weeks of age and their weights tracked weekly.
(D and E) (D) Adiposity (total fat mass/total body mass) and (E) total lean mass after 16 weeks of HFD feeding measured by ECHO-MRI.
(F) Epididymal AT mass.
(G) Mast cell content in epididymal AT shown as the percentage of total CD45+ cells.
(legend continued on next page)
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Figure 4. Kit Deficiency Leads to Profound
Differences in Epididymal AT Gene Expres-
sion during Diet-Induced Obesity
WBB6F1.KitW/Wv, WBB6F1.Cpa3+/+, and
WBB6F1.Cpa3Cre/+ mice were placed on a LFD or
HFD for 12 weeks, and total RNA from their
epididymal AT was isolated for microarray anal-
ysis.
(A) Data were visualized using a principal compo-
nent analysis; black oval represents HFD-fed mice
and red rectangle LFD-fed mice, with the excep-
tion of KitW/Wv mice fed a HFD, which fell into the
LFD-fed group. Gene expression differences be-
tween KitW/Wv, Cpa3+/+, and Cpa3Cre/+ mice fed a
HFD were assessed by a multiple-group Empirical
Bayes statistical test
(B) Genes found to be significantly downregulated
or upregulated between KitW/Wv, Cpa3+/+, and
Cpa3Cre/+ mice are shown in a dendrogram/heat
map hybrid form.
(C and D) Bar graph comparison of the fold-
change between the most significantly upregu-
lated and downregulated genes in (C) HFD-fed
Kit+/+ mice (Cpa3+/+ and Cpa3Cre/+) in comparison
to HFD-fed KitW/Wv mice and in (D) HFD-fed Kit+/+
mice (Cpa3+/+ and Cpa3Cre/+) in comparison to
LFD-fed Kit+/+ mice (Cpa3+/+ and Cpa3Cre/+).
Data are from one experiment with n = 2 to 3 per
group.comparison to the controls when fed a HFD (Figure 6A). Unlike
Kit mutant mice, lymphoid-deficient mice were not protected
from glucose intolerance (Figure 6B), and epididymal AT mass
was also unaffected (Figure 6C). The relative increase in the per-
centages of CD11b+F4/80+ macrophages among total CD45+
cells in the epididymal AT of B6.Rag2/ and B6.Il7r/ mice
when compared to B6.Il7r+/ controls (Figure 6D) was likely
due to the lack/reduction of lymphocytes, as the absolute
number of macrophages per gram of AT was not increased,
but instead trended toward a reduction in these mutants (Fig-
ure 6E). As expected, T (Figures 6F–6H) and B cells (Figures
6F, 6I, and 6J) were completely absent in B6.Rag2/ mice
and severely reduced in B6.Il7r/ mice when compared to
the controls. Collectively, it is unlikely that lymphoid perturba-
tions alone are responsible for the protection from obesity found
in Kit mutant mice. Due to the complexity of the hematopoietic
phenotypes observed in these mutants, new approaches may
be required in the future to definitively pinpoint the cellular or
molecular defects underlying the protection of Kit mutants to
obesity and T2D.
DISCUSSION
Obesity is associated with a state of chronic inflammation that
contributes to the concomitant development of an insulin-resis-(H and I) (H) Fasting plasma triglycerides and (I) total cholesterol after 16 weeks
(J) GTT was performed at 14 weeks of HFD feeding.
Data are represented as mean ± SEM and are pooled from three independent e
weight gain curve and GTT (n = 8–12mice per group). Statistics were performed as
between WBB6F1.Cpa3+/+ and WBB6F1.Cpa3Cre/+ HFD groups versus WBB6F1
Ctant pre-diabetic state that leads to T2D (Hill et al., 2014; Hotami-
sligil and Erbay, 2008). Many immune cells play at least a mini-
mum role in the pathogenesis of obesity (Eheim et al., 2014;
Mraz and Haluzik, 2014), underlining the potential relevance of
multiple hematopoietic lineages for these diseases. The receptor
tyrosine kinase Kit is expressed in the hematopoietic system
in many cell types including stem and progenitor cells, mast
cells, and ILCs, and it plays important roles in hematopoietic
development and homeostasis. Mice with mutations at the
Kit locus (KitW/Wv, KitW-sh/W-sh) are protected from weight gain,
metabolic chronic inflammation, insulin resistance, and T2D
when challenged with HFD feeding. Since Kit mutant mice
lack mast cells, this protection was attributed to the lack of
mast cells (Liu et al., 2009; Tanaka et al., 2011). In this study
we showed that the protective phenotype against these dis-
eases is linked to hematopoietic Kit deficiency rather than
mast cell deficiency.
We have demonstrated the mast cell independence of weight
gain and T2D in three models: (1) In the C57BL/6 background,
mast-cell-deficient Cpa3Cre/+ mice were studied side-by-side
with mast-cell-proficient Cpa3+/+ littermate controls. (2) We
compared leptin-deficient obese mice with (B6.LepOb/Ob
Cpa3+/+) or without (B6.LepOb/ObCpa3Cre/+) mast cells. (3) In
theKitW/Wv strain, we used theCpa3Cre allele to dissociate the ef-
fects of the Kitmutation from the effect of lack of mast cells. Theof HFD-feeding.
xperiments. Each symbol in the dot plots represents one individual mouse for
described for Figure 1 above. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001,
.KitW/Wv HFD group (Kit mutation effect).
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Figure 5. Kit+/+ Bone Marrow Reconstitu-
tion of KitW/WvMice Reverses the Metabolic
Phenotype
WBB6F1.KitW/Wv (KitW/Wv) mice were transplanted
with either WBB6F1.Kit+/+Cpa3+/+ (Cpa3+/+) or
WBB6F1.Cpa3Cre/+ (Cpa3Cre/+) bone marrow;
mice were analyzed or placed on a HFD 6 weeks
after transplantation.
(A) Hematocrit of Kit+/+ and KitW/Wv mice without
transplantation, and that of KitW/Wv mice trans-
planted with Kit+/+ (KitW/Wv (Cpa3+/+ BM)), or with
Cpa3Cre/+ (KitW/Wv (Cpa3Cre/+ BM)) bone marrow.
(B) Gut motility was measured after 90 min of a
FITC-dextran gavage for all indicated groups. Data
are shown as percent fluorescence of each section
of total fluorescence permouse. Data are from one
experiment representative of three independent
experiments.
(C) Fasting glucose levels of all aforementioned
groups.
(D) Weight gain curves of all four groups when
placed on a HFD (n = 4–7).
(E) GTT of all four groups at 14 weeks of HFD
feeding (n = 4–7).
(F–H) (F) Total AT mass measured by ECHO-MRI,
(G) epididymal AT mass, and (H) total lean mass
assessed by ECHO-MRI after 16 weeks of HFD
feeding.
Data are shown as mean ± SEM and are from two
pooled independent experiments. For all dot plot
panels, each dot represents one individual mouse.
Statistics were performed as described for Fig-
ure 1 above. For all studies bone marrow engraft-
ment of CD117+ (Kit+/+) LSKs was confirmed
before inclusion. *p < 0.05; **p < 0.001; ***p <
0.001; ****p < 0.0001 between KitW/Wv mice and
their Kit+/+ and/or KitW/Wv plus BM controls.KitW/Wv mouse, in which published metabolic experiments were
performed, is on the WBB6F1 background. In this background,
we compared Kit+/+Cpa3+/+ (Kit wild-type, mast cell proficient),
Kit+/+Cpa3Cre/+ (Kit wild-type, mast cell deficient), and KitW/Wv
Cpa3+/+ (Kit deficient, mast cell deficient). Mast cell deficiency
did not have an impact on the development of obesity, insulin
resistance, or T2D in any of these experimental systems.
How could the protection of KitW/Wv and KitW-sh/W-shmice from
obesity and insulin resistance be attributed to lack of mast cells?686 Cell Metabolism 21, 678–691, May 5, 2015 ª2015 Elsevier Inc.Mice with naturally occurring mutations in
the Kit locus are mast cell deficient and
have been the mainstay of in vivo mast
cell research for decades (Nakano et al.,
1985). In addition to the well-known pleio-
tropic defects within the immune system,
Kit mutations potentially impair metaboli-
cally relevant cell lineages or tissue func-
tions including hepatic function (Magnol
et al., 2007), insulin secretion from b cells
(Feng et al., 2012), and deficiencies in
neuronal cells both in the enteric (ICC)
and the central nervous system (Huizinga
et al., 1995; Maeda et al., 1992;Milenkovic
et al., 2007; Takagi et al., 2008). UponHFDfeeding, KitW/Wv mice failed to gain AT mass, had hypertriglyceri-
demiaand lowcholesterol levels, andwereprotected fromglucose
intolerance and insulin resistance. Our whole-transcriptomic
expression profiling revealed that Kit-deficient mice fail to enter
the normal gene expression program associated in wild-type
mice with diet-induced obesity; in fact, gene expression in the
AT from KitW/Wv mice on HFD was indistinguishable from normal
mice on a LFD. These results underscore the fundamental resis-
tance of Kitmutant mice to the pathological response to obesity.
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Figure 6. Weight Gain and Glucose Tolerance Are Unaffected by Lymphocyte Deficiency
B6.Rag2/ and B6.Il7r/ mice and B6.IL7r+/ controls were placed on a HFD for 12 weeks.
(A) Their weights were tracked weekly for the duration of the study.
(B) GTT after 9 weeks of HFD feeding.
(C–J) Paramaters after 12 weeks of HFD feeding.
(C) Epididymal AT mass.
(D) Percentage of CD45+CD11b+F4/80+ macrophages from total CD45+ cells.
(E) Absolute number of macrophages per gram of AT.
(F) Representative flow cytometric plots of T (CD45+Siglec-FCD11bF4/80CD19CD3ε+) and B cells (CD45+Siglec-FCD11bF4/80CD3εCD19+) in the AT
of all indicated groups.
(G) Percentage of T cells from total CD45+ cells.
(H) Absolute number of T cells per gram of AT.
(I) Percentage of B cells from total CD45+ cells.
(J) Absolute number of B cells per gram of AT.
Data are shown as mean ± SEM and are from one experiment with n = 3 to 4 per group. Statistics were performed as described for Figure 1 above. ^^p < 0.01
between the weight curves of B6.Rag2/ mice and that of B6.Il7r/ and B6.Il7r+/ mice. *p < 0.05; **p < 0.01; ***p < 0.001 between the indicated groups.
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In recent years, studies in the mast cell field, including the
report by Liu et al. (2009), preferred to use KitW-sh/W-sh mice
over or in addition to KitW/Wv mice, mostly due to claims of a
‘‘milder’’ hematopoietic phenotype, a simpler genetic back-
ground (C57BL/6), and ease of breeding (Grimbaldeston et al.,
2005). However, KitW-sh/W-sh mice, unlike KitW/Wv mice, which
bear point mutations in the Kit gene, have a large genomic inver-
sion located upstream of the Kit locus that potentially impairs the
regulation or function of 28 genes other than Kit, including Corin-
deficiency-associated cardiomegaly (Nigrovic et al., 2008). In the
hematopoetic system, KitW-sh/W-sh mice also display notable de-
fects, including expansion of immature lineage-negative cells,
common myeloid progenitors, granulocyte-macrophage pro-
genitors (i.e., evidence for extramedullarymyelopoiesis), MDSCs
and megakaryocytes in the spleen, and neutrophilia and throm-
bocytosis in the bone marrow (Michel et al., 2013; Nigrovic
et al., 2008). Collectively, key steps in myelopoiesis are defective
in KitW-sh/W-sh mice, casting doubt on the usefulness of this
mutant for Kit studies. Arguably, KitW/Wv mice are the better-
defined model of Kit deficiency.
In any case, the protection of Kit mutants from obesity and
T2D was unrelated to their lack of mast cells, which left open
the possibilities that the metabolic phenotype of these mutant
mice was due to the Kit-dependent defects within or outside
of the immune system. We showed that the protective pheno-
type of KitW/Wv mice was immune regulated, as hematopoietic
reconstitution with Kit+/+ bone marrow into non-irradiated
mice reversed this phenotype. The reversal was also achieved
by using donor bone marrow that was incompetent to generate
mast cells in the KitW/Wv recipient mice (Cpa3Cre/+ HSC), again
supporting the mast cell independence of the process. A com-
plementary experiment would be the reconstitution of KitW/Wv
mice with bone-marrow-derived cultured mast cells. However,
the concept that mast cell functions are revealed by transplan-
tation of cultured mast cells into Kit mutant mice has been
shown to be flawed by experiments in new mouse models.
Roles for mast cell functions that had been proposed based
on the reconstitution system were not reproduced for diverse
pathologies, including antibody-driven arthritis, autoimmune
encephalitis, wound healing (Antsiferova et al., 2013), or con-
tact hypersensitivity (reviewed in Reber et al., 2012; Peschke
et al., 2015). Hence, mast cell reconstitution of Kit mutants,
considered a pillar of immunology (Kawakami, 2009), turned
out to be an unreliable experimental system. This conclusion
is clearly underscored here by the fact that, using multiple inde-
pendent systems, we do not confirm roles for mast cells in pro-
tection of Kit mutant mice from weight gain and insulin
resistance.
This clarification appears important in view of the fact that
mast cells have been proposed as a potential therapeutic
target against obesity and diabetes (Wang and Shi, 2011).
This notion was supported by previous studies showing Kit-
dependent protection from weight gain and insulin resistance
(discussed above) and the promotion of weight loss by daily in-
jections of obese mice with high doses of mast cell stabilizers
(Liu et al., 2009; Wang and Shi, 2011; Wang et al., 2013). In
the Liu et al. (2009) study, mice were injected daily with
25 mg/kg DSCG or ketotifen; this dose highly exceeds the
doses recommended for these drugs in treating asthma and/688 Cell Metabolism 21, 678–691, May 5, 2015 ª2015 Elsevier Inc.or allergy in humans by 37.5-fold (DSCG, 40 mg per day) and
750-fold (ketotifen, 2 mg per day), respectively. Despite using
comparably high dosages, we were unable to replicate weight
loss or prevent weight gain with DSCG. These discrepancies
might be explained by off-target effects of mast cell stabilizers
(Oka et al., 2012), or by other currently unknown factors
including the health status of the mice or different microbiome
enterotypes.
Given the complex nature of the hematopoietic lineages and
stages that are affected by Kit mutations, it remains very chal-
lenging to exactly pinpoint the hematopoietic cell type or its
dysfunction that underlies the protection of Kit mutant mice to
obesity and metabolic syndrome. While we excluded classical
lymphocytes, including ab and gd T cells in the small intestine
by analysis of diet-induced obesity in Rag2- or Il7r-deficient
mice, other interesting cells affected by Kit mutations, notably
ILC subsets, have yet to become more accessible for genetic
experimentation. As for mast cells, Kit-mediated immunological
and non-immunological roles can now be discriminated from
those of mast cells by employing mast-cell-specific deficiency
mouse models (for detailed considerations, see Katz and Aus-
ten, 2011; Peschke et al., 2015; Reber et al., 2012; Rodewald
and Feyerabend, 2012). There are several Kit-independent
models of mast cell deficiency, both constitutive and inducible
(reviewed in Reber et al., 2012), and careful attention must be
placed on choosing the appropriate model for the study of
choice. In our view, Cpa3Cre/+ mice presented the most suitable
model for the current study, as it is the only mouse with com-
plete deficiency of both connective and mucosal tissue mast
cells without deficiencies in other immune or non-immune com-
partments, with the exception of a reduction in basophils.
Especially in chronic disease models, as in obesity studies,
Cpa3Cre/+ mice are advantageous over mice with inducible
mast cell ablation because the latter require repetitive depletion
treatments.
In conclusion, our data showed that obesity, obesity-mediated
insulin resistance, and T2D depend on expression of Kit in the
hematopoietic system but not outside. Since mast cells are
non-essential in the regulation of these diseases, these cells
are unlikely to be successful therapeutic targets. However,
blockade of other Kit-related hematopoietic functions may serve
as potential candidates for the regulation of the metabolic syn-
drome, as long as they are specific enough not to interfere with
basic hematopoietic or immunological functions.
EXPERIMENTAL PROCEDURES
Mice
B6.Cpa3Cre/+ mice were obtained after backcrossing theCpa3Cre allele for >20
generations onto C57BL/6J (B6). In all experiments, littermates from the
breeding of B6.Cpa3Cre/+ with wild-type B6 mice were used. Kit mutant
mast-cell-deficient WBB6F1.KitW/Wv mice and their WBB6F1.Kit+/+ littermate
controls were obtained by crossing WB.KitW/+ with B6.KitWv/+ mice. For direct
comparison, WBB6F1.Cpa3Cre/+ and WBB6F1.Cpa3+/+ littermates were
generated in crosses of WB.Kit+/+ with B6.Cpa3Cre/+ mice. B6.LepOb/Ob
Cpa3Cre/+ mice and their littermate controls were generated by crossing
B6.LepOb/+ with B6.Cpa3Cre/+ mice and intercrossing the F1 generation.
B6.Il7/ and their littermate B6.Il7+/ controls were obtained by intercrossing
B6.Il7+/ mice. B6.Rag2/ were maintained as homozygous knockouts. All
animals were generated at the mouse breeding facilities of the DKFZ in Heidel-
berg. All experiments were conducted in accordance to animal care guidelines
pertaining to local animal committees (Regierungspra¨sidium Karlsruhe) and to
the institutional guidelines (DKFZ, Heidelberg).
Animal Feeding
Experimental animals were maintained with ad libitum access to food and wa-
ter. All feeding studies were started with 8-week-old male or female mice.
Experimental diets were either a HFD (60% kcal from fat; 35% fat content,
Research Diets, Inc.; order number D12492) or LFD (6% crude fat content,
Kliba Nafag; order number 3302). The B6.LepOb/ObCpa3Cre/+ mice and their
littermate controls were always kept on the 6% fat LFD.
Bone Marrow Transplantation
For bone marrow reconstitutions, 6-week-old non-irradiated WBB6F1.KitW/Wv
male mice were transplanted intravenously with 2 3 106 total bone marrow
cells from WBB6F1.Cpa3Cre/+ or WBB6F1.Kit+/+ donors. Only the animals
that were tested positive for donor chimerism (hematocrit R 45%) 6 weeks
after transplantation were used for further experiments.
DSCG Treatment
Male 8-week-old mice were placed on a HFD and injected intraperitoneally
daily with a 25 mg/kg dose DSCG or saline for 7 weeks. Their weights were
tracked weekly for the duration of the study.
Body Weight and Composition
Body weight was measured weekly for the duration of the studies. Total lean
mass, AT mass, and free fluid composition were measured by magnetic reso-
nance imaging using an Echo-MRI-100 system after 8, 12, or 16 weeks of
feeding and after 22 weeks of age for the B6.LepOb/ObCpa3Cre/+ study.
Tissue Collection
After 8 or 16 weeks of feeding or 22 weeks of age, mice were fasted for 5 hr
starting at 7:00 AM and injected intraperitoneally with insulin (1U per kg
body weight of Huminsulin, Eli Lilly) or saline, 15 min prior to euthanasia. Liver,
gastrocnemius muscle, epididymal AT, perirenal AT, spleen, kidneys, and
pancreas were collected post-PBS perfusion. The collected organs were
weighed and distributed for further RNA isolation (stored in RNA later,
QIAGEN), protein extraction (cryofreezing), and formalin-fixed for histological
sectioning and staining.
Protein Purification and Western Blot Analysis
Frozen tissue was homogenized in RIPA lysis buffer for protein extraction. The
amount of protein in the lysates was measured using the BCA Protein quanti-
fication kit (Thermo Scientific). Quantified protein was used for western blot
analysis with antibodies against mouse Akt (clone C67E7), mouse phospho-
Akt (Ser 473) (clone D9E), and b-actin (clone 13E5), all from Cell Signaling
Technology, Inc. The band intensities were quantified using ImageJ software.
Histological Examination of Mast Cells
Portions of the harvested and weighed gastrocnemius muscle and epididymal
AT were formalin-fixed and paraffin-embedded. Tissue was cut into 5 mm sec-
tions and stained with 0.1%w/v toluidine blue O stain (Sigma). Portions of liver
tissue were preserved in Tissue-tek O.C.T compound (Sakura), and 6 mmcryo-
stat sections were made. Liver sections were stained with 0.1% w/v toluidine
blue O stain. Images were taken using a Zeiss Axioplan light microscope at
2003 magnification.
RNA Isolation and qRT-PCR
Liver, gastrocnemius muscle, and epididymal AT were used for RNA purifica-
tion using RNeasy Plus Universal Mini kit (QIAGEN, from muscle) and RNeasy
Plus Mini kit (QIAGEN, from liver and epididymal AT) following manufacturer’s
instructions. Isolated RNA was quantified using the NanoDrop 2000c UV-Vis
Spectrophotometer (Thermo Scientific). cDNA synthesis was carried out
with 400 ng total RNA using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems), following manufacturer’s instructions. Real-time
PCR was performed using the ViiA 7 Real-Time PCR System (Applied
Biosystems). Reactions were carried out using TaqMan Fast Advanced
Master Mix (Applied Biosystems). Gene probes used include Emr1
(Mm00802529_m1), Cpa3 (Mm00483940_m1), Tnf (Mm00443258_m1),CGapdh (Mm99999915_g1), Ccl2 (Mm00441242_m1), Il6 (Mm00446190_m1),
and Cma1 (Mm00487638_m1). The data were analyzed using the Pfaffel
method, and Gapdh expression was used as the housekeeping gene.
AT Microarray
Total RNA was isolated from epididymal AT and used for microarray analysis
using an Illumina Whole-Genome BeadChip Sentrix mouse WG-6 v2 array.
Data were analyzed using the chipster platform and normalized with the quan-
tile normalization method. The accession number for the microarray data re-
ported in this paper is GEO: GSE67091.
GTT and Hematocrit Analysis
Tail vein blood was used for hematocrit analyses using heparinized micro-he-
matocrit capillary tubes and a Thermo scientific capillary centrifugewithmicro-
hematocrit scale. Tail vein blood glucose levels were measured in 8-week-old
mice, prior to being designated to their respective diet groups or 6 weeks after
bonemarrow transplantation. After 6 or 14 weeks of being fed their designated
diets, or 19 weeks of age for the B6.LepOb/ObCpa3Cre/+ study, GTTs were per-
formed on mice that were fasted for 5 hr before baseline blood glucose
measurement. This was followed by intraperitoneal injection of glucose
(0.5 g per kg of body mass) and subsequent measurement of blood
glucose at 15, 30, 45, 60, 90, and 150 min time points.
Plasma Metabolite Measurement
For isolation of blood plasma, approximately 200 ml of blood were collected
from the superficial temporal vein in EDTA-filled tubes (6 ml of 500 mM EDTA
per tube). The sampled blood was centrifuged at 13,000 rpm for 20 min at
4C, and the blood plasmawas separated and stored at80C for further anal-
ysis. Insulin levels of blood plasma were assessed using ELISA (Rat/Mouse In-
sulin 96Well Plate Assay, EMDMillipore), following themanufacturer’s instruc-
tions. Blood plasma was used for cholesterol quantification using the Total
Cholesterol Assay Kit (Cell Biolabs) following manufacturer’s instructions.
Plasma triglycerideswerequantifiedusing the colorimetric SerumTriglycerides
Quantification Kit (Cell Biolabs) following the manufacturer’s instructions.
Stromal Vascular Fraction Isolation and Flow Cytometry
Freshly isolated epididymal AT was weighed, and 0.5 g of AT were digested for
30 min with 1 mg/ml collagenase VIII (Sigma-aldrich) at 37C under constant
shaking (200 rpm). The immune-cell-containing stromal vascular fraction
was separated from the adipocyte fraction by centrifugation and used for
flow cytometry analysis. Stromal vascular fraction cells and whole bone
marrow cells were incubated with total mouse IgG (0.283 mg/ml) (Jackson
ImmunoResearch Laboratories, Inc) for 20 min for Fc blocking. Cells were
then incubated for 45 min with an antibody cocktail mix, discriminative for
the indicated immune cells: mast cells (CD45+CD117+IgE+F4/80), eosino-
phils (CD45+CD11blowF4/80lowSiglecF+), macrophages (CD45+CD11b+F4/80+
SiglecF), CD4+ T cells (CD3+CD4+), CD8+ T cells (CD3+CD8a+), Treg
(CD3+CD4+Foxp3+), B cells (CD19+CD3), and LSKs Lin (CD3, CD4, CD8,
CD19, Ter119, Gr1, NK1.1, CD11b, and CD11c), and CD117+Sca-1+ cells.
The specific clones and fluorochromes utilized for FACS experiments are listed
in Table S1.
Gut Motility Assay
Mice were fasted individually for 90 min in empty mouse cages. After the fast,
water was removed and 15 ml of 70 kDa FITC-labeled dextran (6.25 mg/ml in
0.9% saline) was given to the mice via oral gavage. 90 min later, mice were
euthanized by CO2 asphyxiation, and the GI tract was removed by a subdiaph-
ragmal transection of the esophagus and the colon at the most distal position.
TheGI tract was then divided into 15 fractions, paying careful attention to avoid
movement of intestinal contents; the fractions were divided into stomach, ten
equally sized small intestine fractions, caecum, and three equally sized colon
fragments. The content of each fraction was collected into ice-cold Krebs
buffer, and fluorescence intensity in each fraction was measured using a fluo-
rescence plate reader at 485/528 nm excitation/emission.
Statistical Analysis
Graph Pad Prism software was used for plotting data and for statistical anal-
ysis (Graph Pad Software). Unpaired Student’s t test and one-way ANOVAell Metabolism 21, 678–691, May 5, 2015 ª2015 Elsevier Inc. 689
were used to evaluate statistical significance. Values of p < 0.05 were consid-
ered statistically significant. Statistical significance of data sets that consisted
of more than two variables was analyzed using two-way ANOVA analysis. Data
are presented as mean ± SEM unless noted otherwise.
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